Endocrinology, Vol 137, 3430-3436, Copyright © 1996 by Endocrine Society

ARTICLES

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats

J Pinski, N Lamharzi, G Halmos, K Groot, A Jungwirth, M Vadillo-Buenfil, SS Kakar and AV Schally
Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana 70146, USA.

Continuous exposure to LHRH or its agonistic analogs results in a reduction of LHRH receptor sites and messenger RNA (mRNA) transcripts as well as in desensitization of the pituitary gonadotropes. To determine, whether LHRH antagonists might be similar in this respect to the agonists, we treated male rats for 4 weeks with daily sc injections of LHRH antagonist [Ac-D-Nal2,Phe(4Cl)2,D-Pal(3)3, D-Cit6,D-Ala10]LHRH (Cetrorelix acetate) or LHRH agonist, [D-Trp6]LHRH, in doses of 100 micrograms/animal-day. Another group of rats received a single im injection of 4.5 mg Cetrorelix pamoate depot, a sustained delivery formulation of the LHRH antagonist. An iv stimulation test with LHRH (200 ng/rat) was performed after 4 weeks of treatment. The rats were killed, and pituitary LHRH receptor characteristics were measured by RRA. To examine the effect of LHRH antagonist treatment on the expression of the pituitary LHRH receptor gene, some of the rats injected with Cetrorelix pamoate depot were killed after 2 weeks, and levels of LHRH receptor mRNA were determined by Northern blot and dot blot hybridization to a 32P-labeled rat complementary DNA probe. Our data show that LHRH-stimulated LH secretion at 30 min was suppressed by approximately 33% (P < 0.01) in rats pretreated with [D-Trp6]LHRH compared to that in animals injected with LHRH alone. Pretreatment of the rats with the LHRH antagonist suppressed the LH response to LHRH more markedly, the LH levels at 30 min were decreased by 89.8% and 96% in groups treated with Cetrorelix acetate and Cetrorelix pamoate depot, respectively. The testosterone response was virtually abolished in groups receiving Cetrorelix. The concentration of pituitary receptors for LHRH fell by 69% in the [D-Trp6]LHRH group, whereas the reductions in the Cetrorelix acetate group and in the group that received Cetrorelix pamoate depot were 77% and 82%, respectively. Treatment with Cetrorelix pamoate depot led to a 75-80% decrease in the levels of 5.0- and 4.5-kilobase forms of LHRH receptor mRNA compared to those in the control group. Dot blot analysis also showed 83% reduction in the mRNA for LHRH receptor. In conclusion, these data demonstrate that prolonged administration of LHRH antagonists such as Cetrorelix causes an impairment of gonadotropin secretion and a marked decrease in the levels of LHRH receptors as well as in the expression of the LHRH receptor gene. Thus, the down-regulation of pituitary LHRH receptors produced by LHRH antagonists appears to be similar to that resulting from the agonists.

This article has been cited by other articles:

				T Zhang and M S Roberson Role of MAP kinase phosphatases in GnRH-dependent activation of MAP kinases J. Mol. Endocrinol., February 1, 2006; 36(1): 41 - 50. [Abstract] [Full Text] [PDF]

				K. L. Herbst, A. D. Coviello, S. Page, J. K. Amory, B. D. Anawalt, and W. J. Bremner A Single Dose of the Potent Gonadotropin-Releasing Hormone Antagonist Acyline Suppresses Gonadotropins and Testosterone for 2 Weeks in Healthy Young Men J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5959 - 5965. [Abstract] [Full Text] [PDF]

				J. E. Horvath, G. L. Toller, A. V. Schally, A.-M. Bajo, and K. Groot Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats PNAS, April 6, 2004; 101(14): 4996 - 5001. [Abstract] [Full Text] [PDF]

				H. Zapatero-Caballero, F. Sanchez-Franco, C. Fernandez-Mendez, M. Garcia-San Frutos, L. M. Botella-Cubells, and G. Fernandez-Vazquez Gonadotropin-Releasing Hormone Receptor Gene Expression During Pubertal Development of Female Rats Biol Reprod, February 1, 2004; 70(2): 348 - 355. [Abstract] [Full Text] [PDF]

				H. Zapatero-Caballero, F. Sanchez-Franco, N. Guerra-Perez, C. Fernandez-Mendez, and G. Fernandez-Vazquez Gonadotropin-Releasing Hormone Receptor Gene Expression During Pubertal Development of Male Rats Biol Reprod, May 1, 2003; 68(5): 1764 - 1770. [Abstract] [Full Text] [PDF]

				J. E. Horvath, A. M. Bajo, A. V. Schally, M. Kovacs, F. Herbert, and K. Groot Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats PNAS, November 12, 2002; 99(23): 15048 - 15053. [Abstract] [Full Text] [PDF]

				G. Halmos and A. V. Schally Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix PNAS, January 22, 2002; 99(2): 961 - 965. [Abstract] [Full Text] [PDF]

				M. Kovacs and A. V. Schally Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats PNAS, October 9, 2001; 98(21): 12197 - 12202. [Abstract] [Full Text] [PDF]

				M. Kovacs, A. V. Schally, B. Csernus, and Z. Rekasi Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH PNAS, January 24, 2001; (2001) 31582398. [Abstract] [Full Text]

				E. R. Hernandez Embryo implantation and GnRH antagonists: Embryo implantation: the Rubicon for GnRH antagonists Hum. Reprod., June 1, 2000; 15(6): 1211 - 1216. [Abstract] [Full Text] [PDF]

				C. Albano, J. Smitz, H. Tournaye, H. Riethmuller-Winzen, A. Van Steirteghem, and P. Devroey Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles Hum. Reprod., June 1, 1999; 14(6): 1426 - 1430. [Abstract] [Full Text] [PDF]

				D. C. Danila, A. V. Schally, A. Nagy, and J. M. Alexander Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone PNAS, January 19, 1999; 96(2): 669 - 673. [Abstract] [Full Text] [PDF]

				H. M. Behre, S. Kliesch, G. Puhse, T. Reissmann, and E. Nieschlag High Loading and Low Maintenance Doses of a Gonadotropin-Releasing Hormone Antagonist Effectively Suppress Serum Luteinizing Hormone, Follicle-Stimulating Hormone, and Testosterone in Normal Men J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1403 - 1408. [Abstract] [Full Text] [PDF]

				M. Kovacs, A. V. Schally, B. Csernus, and Z. Rekasi Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH PNAS, February 13, 2001; 98(4): 1829 - 1834. [Abstract] [Full Text] [PDF]